Associations of interleukin-6 with vegetative but not affective depressive symptoms in terminally ill cancer patients

Supportive Care in Cancer

Volumn 21, Issue 8, 2013, Pages 2097-2106

  Inagaki, Masatoshi ^a   Akechi, Tatsuo ^b   Okuyama, Toru ^b   Sugawara, Yuriko ^c   Kinoshita, Hiroya ^d   Shima, Yasuo ^e   Terao, Kimio ^f   Mitsunaga, Shuichi ^d   Ochiai, Atsushi ^d   Uchitomi, Yosuke ^d,g  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NISSAN Motor Health Insurance Society   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

^f CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^g OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cancer; Cytokine; Depression; Fatigue; Sickness behavior; Terminal illness

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANOREXIA; ARTICLE; BLOOD ANALYSIS; CANCER PATIENT; DEPRESSION; FATIGUE; FEMALE; FOLLOW UP; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INSOMNIA; LUNG CANCER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; TERMINALLY ILL PATIENT;

EID: 84879934016     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1767-x     Document Type: Article

References (49)

1. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34(1):94-104. doi: 10.1016/j.jpainsymman.2006.10. 015
2. Dodd MJ, Miaskowski C, Paul SM (2001) Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 28(3):465-470
3. Grassi L, Indelli M, Marzola M, Maestri A, Santini A, Piva E, Boccalon M (1996) Depressive symptoms and quality of life in home-care-assisted cancer patients. J Pain Symptom Manage 12(5):300-307
4. Miaskowski C, Cooper BA, Paul SM, Dodd M, Lee K, Aouizerat BE, West C, Cho M, Bank A (2006) Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: a cluster analysis. Oncol Nurs Forum 33(5):E79-E89. doi: 10.1188/06.ONF.E79-E89
5. Miaskowski C, Lee KA (1999) Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manage 17(5):320-332
6. Cherny NI, Coyle N, Foley KM (1994) Suffering in the advanced cancer patient: a definition and taxonomy. J Palliat Care 10(2):57-70
7. Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y (2004) Suicidality in terminally ill Japanese patients with cancer. Cancer 100(1):183-191. doi: 10.1002/cncr.11890
8. Breitbart W, Rosenfeld B, Pessin H, Kaim M, Funesti-Esch J, Galietta M, Nelson CJ, Brescia R (2000) Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. Jama 284(22):2907-2911
9. Brown JH, Henteleff P, Barakat S, Rowe CJ (1986) Is it normal for terminally ill patients to desire death? Am J Psychiatry 143(2):208-211
10. Chochinov HM, Wilson KG, Enns M, Mowchun N, Lander S, Levitt M, Clinch JJ (1995) Desire for death in the terminally ill. Am J Psychiatry 152(8):1185-1191
11. Henriksson MM, Isometsa ET, Hietanen PS, Aro HM, Lonnqvist JK (1995) Mental disorders in cancer suicides. J Affect Disord 36(1-2):11-20
12. Morita T (2004) Palliative sedation to relieve psycho-existential suffering of terminally ill cancer patients. J Pain Symptom Manage 28(5):445-450. doi: 10.1016/j.jpainsymman.2004.02.017
13. Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Ried LD, Turrisi AT 3rd, Unutzer J, Vernon SW (2003) National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst 95(15):1110-1117
14. Capuron L, Dantzer R (2003) Cytokines and depression: the need for a new paradigm. Brain Behav Immun 17(Suppl 1):S119-S124
15. Maier SF, Watkins LR (1998) Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 105(1):83-107
16. Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH (2009) Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord 119(1-3):181-185. doi: 10.1016/j.jad.2009.02.017
17. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9(1):46-56. doi: 10.1038/nrn2297
18. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH (2002) Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26(5):643-652. doi: 10.1016/S0893-133X(01)00407-9
19. Seow H, Barbera L, Sutradhar R, Howell D, Dudgeon D, Atzema C, Liu Y, Husain A, Sussman J, Earle C (2011) Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 29(9):1151-1158. doi: 10.1200/JCO.2010.30.7173
20. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71(2):171-186. doi: 10.1097/PSY.0b013e3181907c1b
21. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67(5):446-457. doi: 10.1016/j.biopsych.2009.09.033
22. Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K, Flath BC (2006) Biomarkers of depression in cancer patients. Cancer 107(11):2723-2729. doi: 10.1002/cncr.22294
23. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, Nemeroff CB (2001) Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 158(8):1252-1257
24. Soygur H, Palaoglu O, Akarsu ES, Cankurtaran ES, Ozalp E, Turhan L, Ayhan IH (2007) Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31(6):1242-1247. doi: 10.1016/j.pnpbp.2007.05.001
25. Jehn CF, Kuhnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, Flath BC, Luftner D (2010) Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer. Integr Cancer Ther 9(3):270-275. doi: 10.1177/1534735410370036
26. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA 3rd, Cole S, Sood AK, Lubaroff DM (2008) Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26(29):4820-4827. doi: 10.1200/JCO.2007.14.1978
27. Inagaki M, Isono M, Okuyama T, Sugawara Y, Akechi T, Akizuki N, Fujimori M, Mizuno M, Shima Y, Kinoshita H, Uchitomi Y (2008) Plasma interleukin-6 and fatigue in terminally ill cancer patients. J Pain Symptom Manage 35(2):153-161. doi: 10.1016/j.jpainsymman.2007.03.009
28. Kwak SM, Choi YS, Yoon HM, Kim DG, Song SH, Lee YJ, Yeom CH, Koh SJ, Park J, Lee MA, Suh SY (2012) The relationship between interleukin-6, tumor necrosis factor-alpha, and fatigue in terminally ill cancer patients. Palliat Med 26(3):275-282. doi: 10.1177/0269216311406991
29. Akechi T, Okuyama T, Akizuki N, Shimizu K, Inagaki M, Fujimori M, Shima Y, Furukawa TA, Uchitomi Y (2007) Associated and predictive factors of sleep disturbance in advanced cancer patients. Psychooncology 16(10):888-894. doi: 10.1002/pon.1122
30. Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y (2004) Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 22(10):1957-1965. doi: 10.1200/JCO.2004.08.149
31. Akechi T, Okuyama T, Sugawara Y, Shima Y, Furukawa TA, Uchitomi Y (2006) Screening for depression in terminally ill cancer patients in Japan. J Pain Symptom Manage 31(1):5-12. doi: 10.1016/j.jpainsymman.2005.05.016
32. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189-198
33. Mori E, Mitani Y, Yamadori A (1985) Usefulness of a Japanese version of the Mini-Mental State in neurological patients. Shinkeishinrigaku 1(82-90)
34. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), clinician version. American Psychiatric Press, Washington
35. Kitamura T (1993) Hospital Anxiety and Depression Scale (in Japanese). Seisinka Sindangaku 4:371-372
36. Kugaya A, Akechi T, Okuyama T, Okamura H, Uchitomi Y (1998) Screening for psychological distress in Japanese cancer patients. Jpn J Clin Oncol 28(5):333-338
37. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361-370
38. Judd FK, Burrows GD, Lipsitt DR (1991) Handbook of studies on general hospital psychiatry. Elsevier, New York
39. Food and Drug Administration (2001) Guidance for industry, bioanalytical method validation. Food and Drug Administration, Washington
40. Jacobson CM, Rosenfeld B, Pessin H, Breitbart W (2008) Depression and IL-6 blood plasma concentrations in advanced cancer patients. Psychosomatics 49(1):64-66. doi: 10.1176/appi.psy.49.1.64
41. Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP (2012) Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol 39(1):60-62. doi: 10.3899/jrheum.110617
42. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A (2011) Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70(5):755-759. doi: 10.1136/ard.2010.139725
43. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106(8):2627-2632. doi: 10.1182/blood-2004-12-4602
44. Capuron L, Miller AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 130(2):226-238. doi: 10.1016/j.pharmthera.2011.01.014
45. Miaskowski C, Dodd M, Lee K (2004) Symptom clusters: the new frontier in symptom management research. J Natl Cancer Inst Monogr 32:17-21. doi: 10.1093/jncimonographs/lgh023
46. Myers JS (2008) Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum 35(5):802-807. doi: 10.1188/08.ONF.802-807
47. Hamer M, Sabia S, Batty GD, Shipley MJ, Tabak AG, Singh-Manoux A, Kivimaki M (2012) Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. Circulation 126(8):928-933. doi: 10.1161/CIRCULATIONAHA.112.103879
48. Almada C, Cataldo LR, Smalley SV, Diaz E, Serrano A, Hodgson MI, Santos JL (2012) Plasma levels of interleukin-6 and interleukin-18 after an acute physical exercise: relation with post-exercise energy intake in twins. J Physiol Biochem. doi: 10.1007/s13105-012-0191-x
49. Gray SR, Clifford M, Lancaster R, Leggate M, Davies M, Nimmo MA (2009) The response of circulating levels of the interleukin-6/interleukin-6 receptor complex to exercise in young men. Cytokine 47(2):98-102. doi: 10.1016/j.cyto.2009.05.011